SPOTLIGHT: FDA deems Medtronic warning a 'recall'

Oh, by the way, that was a recall. The FDA tells Medtronic that its January warning to doctors--of the increased inflammation risk when its drug infusion systems SynchroMed and IsoMed were used with certain meds--would be classified as a Class I recall. The categorization doesn't change the warning or its recommendations. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.